Cencora, Inc.
COR Healthcare Medical Distribution
Cencora, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $321.3 billion, up 9.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS grew 11.3%, free cash flow grew 3,385.3% and total debt rose 42.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow COR
Cencora, Inc. (COR) EPS (diluted)
Cencora, Inc.'s EPS (diluted) for fiscal 2025 was $7.96, up 5.71% from $7.53 in fiscal 2024. Over the twelve months to 30 June 2026 it was $13.46. Over the past ten years it has ranged from −$16.65 (fiscal 2020) to $8.53 (fiscal 2023); the current reading is higher than 82% of that period. Cencora, Inc. ranks 2nd of 10 Medical Distribution companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $7.96 | 5.71% |
| FY2024 | $7.53 | (11.72%) |
| FY2023 | $8.53 | 6.09% |
| FY2022 | $8.04 | 8.80% |
| FY2021 | $7.39 | — |
| FY2020 | −$16.65 | — |
| FY2019 | $4.04 | (46.35%) |
| FY2018 | $7.53 | 302.67% |
| FY2017 | $1.87 | (70.41%) |
| FY2016 | $6.32 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $3.94 | (53.10%) |
| Mar 2026 | $8.40 | 192.68% |
| Dec 2025 | $2.87 | — |
| Sep 2025 | −$1.75 | — |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MCK McKesson Corporation compare | $37.37 |
| COR Cencora, Inc. | $13.46 |
| CAH Cardinal Health, Inc. compare | $7.23 |
| HSIC Henry Schein, Inc. compare | $3.43 |
| AHG Akso Health Group Sponsored ADR compare | −$0.55 |
| COSM Cosmos Health Inc. compare | −$0.64 |
| FOCL FocalTherics compare | −$1.03 |
| ACH Accendra Health, Inc. compare | −$3.91 |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on COR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement